FEAR & GREED | Business News Interview: How one Aussie city is leading the charge on a medical game changer
Jun 3, 2025
David Hoey, President and CEO of Vaxxas, dives into the future of needle-free vaccine technology, showcasing its potential to enhance immune responses. He discusses the journey from animal trials to human testing and addresses the innovative delivery methods that could transform traditional immunization. The conversation also highlights Brisbane's burgeoning biotech ecosystem and the critical role of mentorship in supporting healthcare innovations. Get ready for a glimpse into the exciting advancements that could reshape vaccine administration!
AI Snips
Chapters
Transcript
Episode notes
Skin-based Vaccine Efficiency
- Needle-free vaccine patches deliver vaccines directly to skin immune cells with 10,000 times higher density than muscle.
- This results in a more efficient, effective immune response compared to traditional needle injections.
Vaccine Stability Without Refrigeration
- Needle-free vaccines in dry patch form can be stored without refrigeration, stable at 40°C for over a year.
- This improves vaccine accessibility in poor infrastructure areas by removing cold chain logistics.
From University Lab to Human Trials
- The vaccine patch technology started at University of Queensland with Prof. Mark Kendall's innovation placing vaccine precisely at skin immune cells.
- Vaxxas developed sterile production processes and completed five phase one human studies, proving technology efficacy.